We are excited to share the latest research paper from Capital Access, alongside the successful completion of our recent capital raise. This milestone reflects significant progress in Duke's growth journey, and we are eager to build on this momentum in the next phase. You can access this paper, along with our investor presentation, on our website here. https://lnkd.in/ejjBGwMC #Research #Equities #UKEquities #AIM #Fundraising #investmentresearch #investorrelations
This morning we have initiated coverage of Duke Capital Limited (LSE: DUKE). #DUKE provides long-term hybrid capital finance to lower-middle market SMEs in a business model unique in the UK. It earns an attractive 12-14% cash yield on initial investment generating reliable cash revenue of c£30m pa, with multiple upside kickers which have generated high returns on recycled investment. Despite increasing returns over WACC, Duke is trading at a discount to its historic rating, which we believe represents a significant opportunity for investors. The company has just announced a conditional £17.2m equity raise with an additional £3m retail offer and plans to attract a further c£100m in third party capital. Duke offers capital preservation, upside on exits and a dividend yield of 9.4%, over four times the average yield on AIM. Read the full note for free on our website, linked below. #Research #Equities #UKEquities #AIM #Fundraising #investmentresearch #investorrelations
CEO & Co-Founder at Marvel Biosciences | Capital Markets and Investment Expert | Finance and Entrepreneurship
1moCongratulations Duke Capital!